AN2 Therapeutics (ANTX) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Outlook Therapeutics (OTLK) over the past year, gaining 254.8% versus a loss of 51.3%. AN2 Therapeutics is the larger company by market cap ($166.0 million vs $145.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | OTLK |
|---|---|---|
| Share price | $4.40 | $0.5989 |
| Market cap | $166.04M | $145.80M |
| 1-day change | -5.98% | +6.19% |
| YTD return | +285.96% | -62.09% |
| 1-year return | +254.84% | -51.31% |
| 5-year return | — | -98.58% |
| EPS (TTM) | $-1.05 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $2.54 |
| 52-week low | $1.00 | $0.161 |
| Distance from 52-week high | -38.80% | -76.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +104.55% | +739.87% |
| Average volume | 237.87K | 13.28M |
| Shares outstanding | 37.74M | 243.45M |
| Employees | 21 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed OTLK by 306.1 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
ANTX vs OTLK FAQ
Which is bigger, AN2 Therapeutics or Outlook Therapeutics?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $166.04M compared with $145.80M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, ANTX or OTLK?
ANTX returned +254.84% over the past 12 months, compared with -51.31% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Outlook Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AN2 Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Outlook Therapeutics.